OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer

Date of occurrence of the event: Nov 21, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A Cause of occurrence: OBI Pharma received a notice from the FDA for orphan drug designation for OBI-888 in treating Pancreatic Cancer. The FDA’s Office of […]